BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20601445)

  • 21. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
    Wang J; Ishii T; Zhang W; Sozer S; Dai Y; Mascarenhas J; Najfeld V; Zhao ZJ; Hoffman R; Wisch N; Xu M
    Leukemia; 2009 Sep; 23(9):1577-86. PubMed ID: 19387466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical requirement for Stat5 in a mouse model of polycythemia vera.
    Yan D; Hutchison RE; Mohi G
    Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
    Gaikwad A; Prchal JT
    Exp Hematol; 2007 Nov; 35(11):1647-56. PubMed ID: 17976517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
    Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
    Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of mutant JAK2V617F for in vitro generation of red blood cells.
    Lee SA; Kim JY; Choi Y; Kim Y; Kim HO
    Transfusion; 2016 Apr; 56(4):837-43. PubMed ID: 26646156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.
    Falchi M; Varricchio L; Martelli F; Marra M; Picconi O; Tafuri A; Girelli G; Uversky VN; Migliaccio AR
    Exp Hematol; 2017 Jun; 50():53-76. PubMed ID: 28232234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice.
    Jin X; Zhao W; Kirabo A; Park SO; Ho WT; Sayeski PP; Zhao ZJ
    J Immunol; 2014 Jul; 193(2):477-84. PubMed ID: 24920845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.
    Steimle C; Lehmann U; Temerinac S; Goerttler PS; Kreipe H; Meinhardt G; Heimpel H; Pahl HL
    Ann Hematol; 2007 Apr; 86(4):239-44. PubMed ID: 17256145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
    Patel AB; Franzini A; Leroy E; Kim SJ; Pomicter AD; Genet L; Xiao M; Yan D; Ahmann JM; Agarwal AM; Clair P; Addada J; Lambert J; Salmon M; Gleich GJ; Cross NCP; Constantinescu SN; O'Hare T; Prchal JT; Deininger MW
    Blood; 2019 Dec; 134(26):2388-2398. PubMed ID: 31697804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme.
    Roda P; Ferrari A; Tang X; Erlich P; Eisenhower C; Patel MD; Irvin-Barnwell EA
    Ann Hematol; 2014 Sep; 93(9):1467-72. PubMed ID: 24687383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant expression of microRNA in polycythemia vera.
    Bruchova H; Merkerova M; Prchal JT
    Haematologica; 2008 Jul; 93(7):1009-16. PubMed ID: 18508790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
    Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
    Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.
    Lu M; Wang J; Li Y; Berenzon D; Wang X; Mascarenhas J; Xu M; Hoffman R
    Blood; 2010 Nov; 116(20):4284-7. PubMed ID: 20625010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
    Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
    Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
    Shi J; Yuan B; Hu W; Lodish H
    Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.
    Chen E; Beer PA; Godfrey AL; Ortmann CA; Li J; Costa-Pereira AP; Ingle CE; Dermitzakis ET; Campbell PJ; Green AR
    Cancer Cell; 2010 Nov; 18(5):524-35. PubMed ID: 21074499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.